PRAX's Quality Score rose 2 points on Mon, Nov 9, to -1.
Follow PRAX's trial news. Pro members can get an alert when Praxis Precision Medicines files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 15% so far from Nov 5 to Nov 9.
“This increase of $359.9 million was primarily attributable to net proceeds from Praxis’ January 2026 follow-on public offering and interest income on marketable securities”
| Holding it back | 35.7% more shares than a year ago |
| Latest filing | 8-K, Nov 9 |
ReportThis morning: the results are out. Past reports ›
TodayPRAX: Praxis Precision Medicines Inc. filed SEC Form 8-K: Results...
Expected to report Thu Feb 18, before the open
The company says its cash lasts into 2028 (8-K, Nov 9).
Director Jill DeSimone sold 11,600 shares on Jun 24, under a planned sale.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Poorfor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
PRAX is #166 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 166 |
Cash and short-term investments: PRAX $759M, PTCT $2.23B, MBX $419M, AXSM $320M.
Expected to report Thu Feb 18, before the open (in 101 days).
It is reacting right now. PRAX reported Nov 9, 2026 before the open, and this session is still open, so the reaction is still being made. It lands in the table below once the session settles.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“This increase of $359.9 million was primarily attributable to net proceeds from Praxis’ January 2026 follow-on public offering and interest income on marketable securities, partially offset by cash used in operations.”
PRAX's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase in general and administrative expenses of $30.1 million was primarily attributable to $17.2 million in increased personnel-related expenses, $9.4 million in increased professional expenses and $3.5 million increase in other expenses.”
From its results filing (SEC filing · Nov 9)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Aug 6, 2026 | +9.8% | +15.9% | +21.0% |
| May 7, 2026 | -0.7% | -1.0% | +3.7% |
| Feb 19, 2026 | -4.2% | +0.8% | +5.7% |
Sales grew in two of the last three years, to $0 in 2025. It lost money in each of the four years.
RSI 58.9, MACD above signal, above its 50-day, below its 200-day. Not scored.
2 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: PRAX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
“The biopharmaceutical industry is characterized by rapidly advancing technologies, strong competition and an emphasis on proprietary products.”
PRAX scores -1 today, which Breakaway calls Poor. It is #166 of 281 in Biotech by Quality Score, with 4 of 14 chart checks firing. Up 15% so far from Nov 5 to Nov 9. Shares: 37.2% more than a year ago (to Dec 31). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
PRAX scores -1 today, which Breakaway calls Poor (below zero). That is #166 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind PRAX's -1.
Expected to report Thu Feb 18, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. PRAX closed higher after 2 of its last 3 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free for 24 hours. No account. No card. Then keep going with a free account.